NUGN
0.186
-0.006 (-3.12%)

Strategy & History

 

NuGene initially focused on providing stem cell derived medical products to medical providers. These products included Plasma Rich Platelet (PRP) and Stem Cell injections for orthopedic and plastic surgery procedures.

In 2011 the founders decided to use adult adipose human stem cells as the foundation of the formulation for its product line. Through their research and development they developed a proprietary process to extract human adult stem cells from fat cells that are used in the customized NuGene line (celebrity collection) made specifically for client(s) donating their own fat tissues.

The Company though this process developed the ability to culture adult human stem cells to render human conditioned stem cell media at proprietary concentrations (which is the primary ingredient in the NuGene line of Cosmeceuticals).

In 2012, NuGene completed their initial line of cosmeceutical products based on adipose derived stem cells.

Throughout 2013 NuGene continued to expand the product offerings of the skincare and haircare line. The Company focused its stem cell work on the surgical arena and orthopedic regeneration. Sales of the NuGene Line were limited through this initial rollout and branding phase.

It was decided that Plasma Rich Platelet (PRP) and Stem Cell injections for orthopedic and plastic surgery procedures had limited growth potential and thus NuGene changed its focus to developing skincare and haircare cosmeceuticals which has a much larger market potential.

NuGene focused efforts in 2014 on transitioning to a cosmeceutical skincare and haircare business for mass distribution. The Company directed significant time and resources developing anti-aging and scar treatment/reduction products.

The category of skincare products based on biotechnology, such as human stem cell, is just beginning to be developed and therefore we expect that it has significant growth potential. NuGene’s goal is to leverage its knowledge of human stem cell technology to develop and commercialize advanced anti-aging skincare products for retail and professional channels. NuGene develops, manufactures, and markets cosmetic skincare and haircare products to address this significant market opportunity.

NuGene has initially focused on national distribution through medical offices and medical spas. As part of that focus the company has sought to leverage the close relationships with the plastic surgery community developed by its founders.

In November 2014, the company entered into a License Agreement with kathy ireland Worldwide Inc. whereby NuGene licensed the right to utilize the trademarks and rights to the name, likeness and visual representations of Kathy Ireland in connection with their cosmeceutical line of products containing adult human adipose stem cell derived or containing biologically active or biologically derived ingredients.

NuGene believes that their proprietary concentration in conjunction with their unique formulations, licensing agreement and industry relationships will provide a significant competitive advantage.

The company in addition has initiated preclinical FDA work for a new topical drug (drug intended for delivery through the skin) for the treatment of burns that is expected to not only reduce infection (silver sulfadiazine), but also enhance tissue growth. Burns are the fourth most common type of trauma worldwide.

The Company has continued to assemble an Advisory Board consisting of Board Certified Dermatologists, Plastic Surgeons and Burn Specialists consisting of medical professionals whom the Company believes are leaders in their respective fields.

Board of Directors

Ali Kharazmi, J.D., M.B.A., CEO & Director Education:

Juris Doctorate 1997, Masters in Business Administration 1983

Bachelors of Arts in Economics 1980, Vice President of Business Development for Republic Health 1986-1988, the third largest For Profit Hospital Group.

Medical Information Networks: (1998-2003)
Co-Founder of one of the first medical technology companies to provide electronic prescription services and formulary control with e-detailing to physicians by pharmaceutical companies. This type of transaction was done via a handheld device using the internet and allowed the sponsoring company to have immediate access to the physician history.

Newport Beach Plastic Surgery: (2003-2005)
Co-Founder of one of the largest staff model plastic surgery multi-site medical groups in California.

Multi-site outpatient surgical facility company: (2004-2005)
Co-Founder

Genetic Institute of Anti-Aging & Center for Weight Management and plastic surgery: (2005-present)
Co-Founder of a comprehensive center for analysis of a patient’s comprehensive physical condition.

Advanced Surgical Partners: (2005-present)
Co-Founder and CEO

Founder-Regenerative Institute: (2012-present)
A research lab that works exclusively on stem cell related research and treatment methods.

OrthoRegeneration: (2012-present)
Co-Founder of a Sport and Orthopedic Regeneration company specializing in PRP and Adult Human Adipose stem cell based regenerative services.

M. Saeed Kharazmi, M.D., Chairman & Chief Technology Officer

M. Saeed Kharazmi, MD obtained his Medical Degree from University of California, Irvine in 1992 and completed his Residency and Chief Residency at St. Mary Medical Center/UCLA in 1996. In 2014 Dr. Kharazmi joined UCR as HS Assistant Clinical Professor and became the Medical Director of UCRHealth, a university hospitalist group. He is also the acting Medical Director for Advanced Surgical Partners, a multispecialty surgical facility, that he and his brother started in 2004. His interest in Age Management and Research led to the development of Genetic Institute of Anti-Aging in 2005 where he became co-founder of NuGene, a cosmeceutical company. Dr. Kharazmi led the Nugene scientific team to introduce new active ingredients for skin rejuvenation and wound healing.

The Team

Sanjay Dhar, Ph.D.

Executive Director of Research and Development

Dr. Sanjay Dhar was Founding Director of Center for Tissue Engineering & Regenerative Medicine at Aesthetic & Plastic Surgery Institute, University of California, Irvine. He is one of the world’s most outstanding scientists and a foremost leader in adipose derived stem cells research.

Obtaining an M.S. & M.Phil., from University of Kashmir India, and Ph.D. from Indian Veterinary Research Institute, India; he went on to be a Visiting Fellow at Center for Biologics Evaluation & Research, Food & Drug Administration, (CBER/FDA, Bethesda. MD) followed by being a Visiting Sr. Associate at New England Medical Center (New England Medical Center, Boston). He joined Institute for Molecular Medicine as a Research Scientist for a brief stint but his passion for research brought him to University of California, Irvine where he joined as a Professional Researcher in the Division of Plastic Surgery and built its research program. After the establishment of Aesthetic & Plastic Institute at UCI, he became the Director of the Research for the institute wherein he started various research programs focused on peripheral nerve regeneration, and bone & cartilage regeneration
using growth factors and adipose derived stem cells.

He was a part of the team which showed that adipose derived stem cells can be differentiated into bone and cartilage and these differentiated cells along with prefabricated biodegradable polymers can be used for the treatment of bone and cartilage defects. He also developed a model of delivering nerve growth factor to the severely injured peripheral nerves for its recovery, regeneration and regaining of the function. He owns various patents for his pioneering work in these areas of research. He has vast experience in the area of stem cell research, translational sciences and its therapies.

Dr. Dhar organized and Co-chaired the 4th California Tissue Engineering Meeting and is a life member of various international societies, has published numerous papers in peer reviewed journals and has presented his work a number of conferences. He has delivered guest lectures here and abroad and is recipient of numerous awards for his pioneering work. Besides his interest in research, he has imparted research trainings and mentored about fifty students in the area of tissue engineering. His academic interest has also led him to be a member of School Site Council at Irvine Unified School District. Prior to joining NuGene, Inc., he was the Vice President, Science & Technology at Stem Cells on Wheels, Irvine, CA.

Fady Elias, M.D.

Director of Professional Business Development
Sports medicine orthopedics Orthobiologics specialist

Dr. Elias graduated from the University of Washington with a bachelor of science degree in molecular and cellular biology. He then completed his medical school at the prestigious university of Washington school of medicine graduating with distinction and as the youngest graduate in his class. He pursued postgraduate training at Stony Brook University Hospital in New York and the Cleveland Clinic in Ohio.

Dr. Elias practices orthopedic sports medicine and specializes in orthobiologics, the use of stem cells in treating orthopedic injuries and disease. He has treated several professional athletes as well as patients from all over the world.

He was asked to join NuGene two years ago as VP of business development. This was a natural fit given that he treats patients with autologous stem cells in his own clinical practice. He has been responsible for the expansion of the NuGene brand and creating brand awareness. His ability to simplify the science of NuGene in a simplified yet thorough manner has been essential in gaining organic traction and sales growth.

Shahrokh Zekavati, Ph.D.

Chemist, Executive Director of Manufacturing

Dr. Shahrokh Zekavati joined NuGene, Inc with 30 years of Cosmetic and Pharmaceutical Industry experience and a strong educational background. He earned his Doctorate of Engineering and Master of Science in Physical Organic Chemistry from the University of Science and Technology at Languedoc – Montpellier (France) and Engineer in Training (EIT) from CA, USA.

He also earned another Master of Science and Bachelor of Science in Chemical Engineering from Tehran University (Iran). He is one of the primary developers of pain relief and anti-inflammatory products line and is continuously contributing to scientific research and product development. With his knowledge and experience in formulation, operation and documentation, Shahrokh operates as a liaison between NuGene and new product requests.

 

Kathy M. Anderson, M.D., FACOG, J.D.

Medical Education and Licensure:

Fellow of the American College of Obstetrics and Gynecology

Diplomate of American Board of Obstetrics and Gynecology

California Medical License: 2-2-94 to Present

Diplomate of National Board of Medical Examiners

Assistant Clinical Professor in Dept. of Ob/Gyn: 8/2004

University of California, Irvine

UCI Medical Center

Orange, CA. 92863

Residency Obstetrics and Gynecology, LLUMC: 1992-1996

Robert Wagner, MD, Program Director

LLU Medical Center

Loma Linda, CA 92354

Loma Linda University, School of Medicine: M.D. (Honors) 1989-1992

Dr. Douglas Will, Dean of Medical School

LLU School of Medicine

Loma Linda, CA 92354

Oral Roberts University, School of Medicine: 1988-1989

Larry Edwards, MD

Dean of Medical School, ORU

7777 S Lewis

Tulsa OK 74171

Oral Roberts University: B.S., 1981-1985—with honors

Dr. Carl Hamilton, Dean

Special legal Training:

International Law- July 2004, Toulouse, France

International Law; Sexual orientation and the Law- July 2005, Netherlands

Special Medical Training:

Certified in multiple aesthetic procedures, including lasers and aesthetic injections, 2007

Certified in Lipodissolve procedures, 2007

Operative Hysteroscopy – 1997

Operative Laparoscopy Course, 9-24-94, LLUMC

Microsurgical Techniques Course, 10-16-95, LLUMC

Laser Surgical Principles and Techniques, 5-10-96, LLUMC